Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

Published:2023-11 Issue: Volume:65 Page:102237
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Rohde Gernot^ORCID,Stenglein Stephan,Prozesky Hans^ORCID,Manudhane Ganesh,Sandulescu Oana,Bauer Martin,Overend Tim,Koch Winfried,Neuschwander Dennis,Planz Oliver,Torres Antoni,Witzenrath Martin

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Evolution of practices regarding COVID-19 treatment in France during the first wave: results from three cross-sectional surveys (March to June 2020);Rolland;J Antimicrob Chemother,2021

2. A first draft of the history of treating coronavirus disease 2019: use of repurposed medications in United States hospitals;Clancy;Open Forum Infect Dis,2020

3. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19;Cao;N Engl J Med,2020

4. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses;Schreiber;Cell Mol Life Sci,2022

5. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo;Pinto;Antiviral Res,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections;International Journal of Molecular Sciences;2024-06-25

2. MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection;Frontiers in Immunology;2024-06-24